Explore the vast range of titles available.

Amphiphilic fluorocarbon substances are a trending topic of research due to their wide range of applications accompanied by an alarming environmental and health impact. In order to predict their fate in the environment, use them more economically, develop new water treatment methods, etc., a better understanding of their physicochemical behavior is required. Their hydrophobicity in water/oil systems is particularly sensitive to one key thermodynamic parameter: the free energy of transfer of a perfluoromethylene group from oil to water. However, for the –CF[sub.2]– moiety, the transfer energy values reported in the literature vary by more than ±25%. Due to the exponential relationship between this energy and the adsorption constants or the partition coefficients, such an uncertainty can lead to orders of magnitude error in the predicted distribution of fluorinated species. We address this problem by presenting an experimental determination of the hydrophobic effect of a –CF[sub.2]– moiety with a greater certainty than currently available. The transfer energy is determined by measuring the interfacial tension of water|hexane for aqueous solutions of short-chained fluorotelomer alcohols. The obtained results for the free energy of transfer of a –CF[sub.2]– moiety from oil to water are 1.68±0.02×RT[sub.0], 1.75±0.02×RT[sub.0], and 1.88±0.02×RT[sub.0] at 288.15 K, 293.15 K, and 303.15 K, respectively.

Endocrine disruptors are a group of chemical compounds that, even in low concentrations, cause a hormonal imbalance in the body, contributing to the development of various harmful health disorders. Many industry compounds, due to their important commercial value and numerous applications, are produced on a global scale, while the mechanism of their endocrine action has not been fully understood. In recent years, per- and polyfluoroalkyl substances (PFASs) have gained the interest of major international health organizations, and thus more and more studies have been aimed to explain the toxicity of these compounds. PFASs were firstly synthesized in the 1950s and broadly used in the industry in the production of firefighting agents, cosmetics and herbicides. The numerous industrial applications of PFASs, combined with the exceptionally long half-life of these substances in the human body and extreme environmental persistence, result in a common and chronic exposure of the general population to their action. Available data have suggested that human exposure to PFASs can occur during different stages of development and may cause short- or/and long-term health effects. This paper synthetizes the current literature reports on the presence, bioaccumulation and, particularly, endocrine toxicity of selected long- and short-chain PFASs, with a special emphasis on the mechanisms underlying their endocrine actions.

Per- and polyfluoroalkyl substances (PFAS) involve multiple per- and polyfluorinated compounds that are widely used globally. Legacy PFAS, including PFOA, PFOS, and PFHxS, were manufactured before 2000 in various industrialized nations, then gradually phased out in accordance with the Stockholm Convention. Due to the substantial accumulation of these legacy PFAS compounds, their concentrations in drinking water are regulated in some countries. This review first summarizes the historical background of PFAS, followed by a description of their chemical properties. The clinical manifestations of legacy PFAS in humans, such as dyslipidemia, attenuated immune function, and chronic kidney disorders, are also summarized. Emerging PFAS involve Gen-X and F-53B as well as numerous newly developed chemicals with their associated precursors/metabolites, including volatile PFAS. Research on these emerging PFAS compounds in the environment continues to grow, building a substantial body of evidence about their effects. The chemical structure of emerging PFAS shows a wide variety: they could contain ether, ester, sulfoneamide, and other halogen atoms rather than fluorine. Volatile PFAS involve the fluorotelomer 6:2 FTOH and other short-chain PFAS compounds, which are best measured by GC-MS. This review also briefly summarizes the assay for total oxidizable precursors of PFAS, an LC-MS-based assay for an emerging assay that will be used for a quantitative estimation of total PFAS, including emerging PFAS.

Various countries have instituted risk governance measures to control and minimize the risks of chemicals at the national and international levels. Activities typically include risk assessment based on ) hazard and exposure assessments; ) setting limits on the production, use, and emissions of chemicals; ) enforcement of regulations; and ) monitoring the effectiveness of the measures taken. These steps largely depend on chemical analysis and access to pure chemical reference standards. However, except for specific highly regulated categories of chemicals, such reference standards often are not commercially available. This raises a critical question: Given the widespread lack of reference standards, is the current approach to governing chemicals adequate to protect humans and the environment from harm? If not, what measures could be taken to improve the situation? We outline how current chemical risk governance is hampered by the widespread lack of reference standards to produce the required scientific evidence. We also provide a list of recommendations for controlling chemical risks in the absence of reference standards. We use per- and polyfluoroalkyl substances (PFASs), specifically the chemical C6O4 [perfluoro ([5-methoxy-1,3-dioxolan-4-yl]oxy) acetic acid], to illustrate how companies that produce chemicals can prevent access to reference standards. We argue that the very limited availability of reference standards undermines the ability of scientists to produce independent scientific evidence needed for chemical risk governance and, thereby, prevents society from protecting people and the environment against chemical pollution and its harms. Possible ways to improve the situation include ) guaranteeing access to chemical reference standards by creating a reference standards repository, ) redefining the level of confidence sufficient for regulatory action, ) providing alternative options for chemical identification and quantification when reference standards are not available, and ) considering, when no reference standards are available, regulation of chemicals by class rather than individually. https://doi.org/10.1289/EHP12331.

Perfluoroalkyl substances (PFAS) are a group of widely used persistent chemicals with suspected immunotoxic effects. The present study aimed to examine the association between infant PFAS exposure and antibody responses to measles vaccination as well as morbidity in a low-income country. In a randomized controlled trial, children from Guinea-Bissau, West Africa, were followed from inclusion (4-7 months of age) through 2 years of age. Half the children received two measles vaccinations (at inclusion and at 9 months of age), and the other half received only one (at 9 months of age). In a subset of 237 children, six PFAS were quantified in serum at inclusion, and measles antibody concentrations were assessed at inclusion and at approximately 9 months and 2 years of age. At inclusion and at the 9-month visit, mothers were interviewed about infant morbidity. All but one child had detectable serum concentrations of all six PFAS, although levels were lower than seen elsewhere. A doubling in perfluorooctane sulfonic acid (PFOS) and perfluorodecanoic acid (PFDA) were associated with 21% (95% CI: 2, 37%) and 25% (95% CI: 1, 43%), respectively, lower measles antibody concentrations at the 9-month visit among the children who had received a measles vaccine at inclusion. Elevated serum PFAS concentrations were also associated with reduced prevaccination measles antibody concentrations and increased morbidity. The present study documents that PFAS exposure has reached West Africa and that infants show PFAS-associated increases in morbidity and decreases in measles-specific antibody concentrations before and after vaccination. These findings support the evidence on PFAS immunotoxicity at comparatively low serum concentrations. https://doi.org/10.1289/EHP6517.

Due to their unique chemical properties, per- and polyfluoroalkyl substances (PFAS) have been used extensively as industrial surfactants and processing aids. While several types of PFAS have been voluntarily phased out by their manufacturers, these chemicals continue to be of ecological and public health concern due to their persistence in the environment and their presence in living organisms. Moreover, while the compounds referred to as “legacy” PFAS remain in the environment, alternative compounds have emerged as replacements for their legacy predecessors and are now detected in numerous matrices. In this review, we discuss the historical uses of PFAS, recent advances in analytical techniques for analysis of these compounds, and the fate of PFAS in the environment. In addition, we evaluate current biomonitoring studies of human exposure to legacy and emerging PFAS and examine the associations of PFAS exposure with human health impacts, including cancer- and non-cancer-related outcomes. Special focus is given to short-chain perfluoroalkyl acids (PFAAs) and ether-substituted, polyfluoroalkyl alternatives including hexafluoropropylene oxide dimer acid (HFPO-DA; tradename GenX), 4,8-dioxa-3H-perfluorononanoic acid (DONA), and 6:2 chlorinated polyfluoroethersulfonic acid (6:2 Cl-PFESA; tradename F-53B).

The toxicity and environmental persistence of anthropogenic per- and poly-fluoroalkyl substances (PFAS) are of global concern. To address legacy PFAS concerns in the United States, industry developed numerous replacement PFAS that commonly are treated as confidential information. To investigate the distribution of PFAS in New Jersey, soils collected from across the state were subjected to nontargeted mass-spectral analyses. Ten chloroperfluoropolyether carboxylates were tentatively identified, with at least three congeners in all samples. Nine congeners are ≥(CF₂)₇. Distinct chemical formulas and structures, as well as geographic distribution, suggest airborne transport from an industrial source. Lighter congeners dispersed more widely than heavier congeners, with the most widely dispersed detected in an in-stock New Hampshire sample. Additional data were used to develop a legacy-PFAS fingerprint for historical PFAS sources in New Jersey.

Per- and polyfluoroalkyl substances (PFAS) threaten ecosystems worldwide due to their persistence, bioaccumulation, and toxicity. Through a global-scale meta-analysis of 119 aquatic and terrestrial food webs from 64 studies, we analyse 1009 trophic magnification factors (TMFs) for 72 PFAS and identify key variability drivers. On average, PFAS concentrations double with each trophic level increase (mean TMF = 2.00, 95% CI:1.64-2.45), though magnification varies considerably by compound. Notably, the industrial alternative F-53B exhibits the highest magnification (TMF = 3.07, 95% CI:2.41-3.92), a critical finding given its expanding use and minimal regulatory scrutiny. Methodological disparities across studies emerge as the dominant source of TMF variability. Our models explain 85% of the variation in TMFs, underscoring predictive capacity. This synthesis establishes PFAS as persistent trophic multipliers and provides a framework to prioritise high-risk compounds and harmonise biomagnification assessments. Our results call for consideration of stricter PFAS regulation to curb cascading ecological and health impacts. PFAS are “forever chemicals” that build up in living things and can move through food webs. This study shows their levels roughly double with each step up the food chain, highlighting widespread chemical magnification in nature.

Perfluorohexyloctane ophthalmic solution (Miebo ® ) is a single-entity, water-, steroid- and preservative-free, first-in-class semifluorinated alkane that is approved in the USA for the treatment of the signs and symptoms of dry eye disease (DED). DED is often linked with meibomian gland dysfunction (MGD), which causes an excessive evaporation of tears. Perfluorohexyloctane ophthalmic solution stabilizes the lipid layer of the tear film and inhibits tear evaporation by forming a monolayer at the air-liquid interface. In the phase III GOBI and MOJAVE trials in adults with DED associated with MGD, one drop of perfluorohexyloctane ophthalmic solution instilled in each eye four times daily over 8 weeks resulted in statistically significant and clinically meaningful improvements in the signs and symptoms of DED compared with hypotonic saline (0.6%). The agent was generally well tolerated, with most ocular adverse events being mild or moderate in severity. The efficacy and tolerability of perfluorohexyloctane ophthalmic solution was sustained for up to 52 weeks in an extension study (KALAHARI). As the first and currently the only prescription treatment approved in the USA directly addressing the pathophysiology of excessive tear evaporation, perfluorohexyloctane ophthalmic solution is a valuable emerging option for the management of DED. Plain Language Summary Dry eye disease (DED) is a common eye disorder caused by many factors. In most cases, DED is linked with meibomian gland dysfunction (MGD), which causes an excessive evaporation of tears. Perfluorohexyloctane ophthalmic solution (Miebo ® ), a single-entity, water-, steroid- and preservative-free, first-in-class semifluorinated alkane, is approved in the USA for the treatment of the signs and symptoms of DED. The agent stabilizes the lipid layer of the tear film and prevents the evaporation of tears by forming a layer on the surface of the tear film. In two phase III clinical trials in adults with MGD-associated DED, one drop of perfluorohexyloctane ophthalmic solution instilled in each eye four times daily over 8 weeks led to significant improvements in the signs and symptoms of DED when compared with hypotonic saline (0.6%). Perfluorohexyloctane ophthalmic solution was generally well tolerated, with most ocular adverse events being mild or moderate in severity. Thus, as the first and currently the only prescription treatment approved in the USA directly addressing excessive tear evaporation, perfluorohexyloctane ophthalmic solution is a valuable emerging option for the management of DED.